Recent data have established the HIV-1 and SIV escape CTL through epitope mutation. However, three novel studies prove that such escape comes at a "cost" to overall viral fitness. Understanding how HIV-1/SIV escape CTL and the impact of the escape mutations has tremendous importance in developing CTL based vaccines. Further, a CTL based HIV-1 vaccine is likely to have long-term protective effect against disease only if the escape virus is significantly weakened compared with wild type.
No takes yet. Share an insight, caveat, or question.
Stephen M. Smith (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: